BACKGROUND: Diminished cytokine production in infancy has been associated with an increased risk for allergen sensitization and early-life wheeze. OBJECTIVE: We sought to assess the effect of low cytokine production in the first year of life on the development of wheeze through age 13 years. METHODS: Cytokine production (IFN-gamma and IL-2) by mitogen-stimulated mononuclear cells was determined from peripheral blood samples (9.4 months, n = 118) in a subset of healthy infants enrolled in the Tucson Children's Respiratory Study. The occurrence of wheeze during the previous year was ascertained at ages 2, 3, 6, 8, 11, and 13 years by means of questionnaire. Relative risk for wheeze was computed with generalized estimating equations. RESULTS: The risk of wheezing between 2 and 13 years was significantly higher for subjects with low 9-month IFN-gamma production (relative risk, 2.29; 95% CI, 1.35-3.89) and borderline significant for those with intermediate IFN-gamma production (relative risk, 1.59; 95% CI, 0.95-2.68) compared with those who produced high levels of IFN-gamma (P value for linear association = .002). Nine-month IL-2 production was unrelated to wheeze. In relation to complex wheezing phenotypes, 9-month IFN-gamma production was inversely related to toddler wheeze (occurring only before age 6 years, P = .03) and chronic wheeze (occurring before and after age 6 years, P = .007) but not school-age wheeze (occurring only after age 6 years, P = .06). CONCLUSION: The results suggest that characteristics of the immune system present during the first year of life can anticipate the likelihood of development of episodes of airway obstruction characterized by wheezing. CLINICAL IMPLICATIONS: Immune susceptibility to asthma is established very early during postnatal life.
BACKGROUND: Diminished cytokine production in infancy has been associated with an increased risk for allergen sensitization and early-life wheeze. OBJECTIVE: We sought to assess the effect of low cytokine production in the first year of life on the development of wheeze through age 13 years. METHODS: Cytokine production (IFN-gamma and IL-2) by mitogen-stimulated mononuclear cells was determined from peripheral blood samples (9.4 months, n = 118) in a subset of healthy infants enrolled in the Tucson Children's Respiratory Study. The occurrence of wheeze during the previous year was ascertained at ages 2, 3, 6, 8, 11, and 13 years by means of questionnaire. Relative risk for wheeze was computed with generalized estimating equations. RESULTS: The risk of wheezing between 2 and 13 years was significantly higher for subjects with low 9-month IFN-gamma production (relative risk, 2.29; 95% CI, 1.35-3.89) and borderline significant for those with intermediate IFN-gamma production (relative risk, 1.59; 95% CI, 0.95-2.68) compared with those who produced high levels of IFN-gamma (P value for linear association = .002). Nine-month IL-2 production was unrelated to wheeze. In relation to complex wheezing phenotypes, 9-month IFN-gamma production was inversely related to toddler wheeze (occurring only before age 6 years, P = .03) and chronic wheeze (occurring before and after age 6 years, P = .007) but not school-age wheeze (occurring only after age 6 years, P = .06). CONCLUSION: The results suggest that characteristics of the immune system present during the first year of life can anticipate the likelihood of development of episodes of airway obstruction characterized by wheezing. CLINICAL IMPLICATIONS: Immune susceptibility to asthma is established very early during postnatal life.
Authors: Hooman Mirzakhani; Vincent J Carey; Robert Zeiger; Leonard B Bacharier; George T O'Connor; Michael X Schatz; Nancy Laranjo; Scott T Weiss; Augusto A Litonjua Journal: Clin Exp Allergy Date: 2019-01-03 Impact factor: 5.018
Authors: Emma E Thompson; Rachel A Myers; Gaixin Du; Tessa M Aydelotte; Christopher J Tisler; Debra A Stern; Michael D Evans; Penelope E Graves; Daniel J Jackson; Fernando D Martinez; James E Gern; Anne L Wright; Robert F Lemanske; Carole Ober Journal: J Allergy Clin Immunol Date: 2013-02-21 Impact factor: 10.793
Authors: Daniel J Jackson; Ronald E Gangnon; Michael D Evans; Kathy A Roberg; Elizabeth L Anderson; Tressa E Pappas; Magnolia C Printz; Wai-Ming Lee; Peter A Shult; Erik Reisdorf; Kirsten T Carlson-Dakes; Lisa P Salazar; Douglas F DaSilva; Christopher J Tisler; James E Gern; Robert F Lemanske Journal: Am J Respir Crit Care Med Date: 2008-06-19 Impact factor: 21.405